Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

83.02 +2.08 (+2.57%)
Streaming Delayed Price Updated: 1:26 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
49 50 Next >
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped. 
Via Investor's Business Daily
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
Roche isn't the only company working on an anti-TIGIT molecule. 
Via Investor's Business Daily
Gilead Sciences Presents at ECCMID 2022 - Continues Mission to Advance Access to Effective Therapies
SOURCE: Gilead Sciences 
Via 3BL Media
Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings
Via Benzinga
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
RBC Capital Markets views Galapagos' NV (NASDAQ: GLPG) Q1 Jyseleca revenues in line as the story focuses on whether new leadership can unlock value from GLPG's ample balance sheet. 
Via Benzinga
Why These Analysts Are Bullish On Gilead's Q1 Earnings
Via Benzinga
Gilead Sciences Crushes First-Quarter Views As Covid Drug Adds $1.5 Billion
The company said quarterly sales rose 2% excluding the impact of Veklury. 
Via Investor's Business Daily
Recap: Gilead Sciences Q1 Earnings
Gilead Sciences (NASDAQ:GILD) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Closing the Representation Gap in Schools, One Black Male Teacher at a Time
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Product Recall
Exposures Legal Product Safety
Pfizer: The Treasure of Albert Bourla
Pfizer won the lottery with Covid-19, but how it invests that cash will determine how well the stock does in the longer-term. 
Via InvestorPlace
May 2022 Stock Considerations
Let’s take a look at my May stock considerations. 
Via Talk Markets
Opinion: The Road to Ending Visceral Leishmaniasis
SOURCE: Gilead Sciences 
Via 3BL Media
Bio-based Platform Chemicals Market Size Estimated to Reach US$26.3 billion by 2027
Bio-based Platform Chemicals Market Size Estimated to Reach US$26.3 billion by 2027 Bio-based Platform Chemicals Market Overview The Bio-based Platform Chemicals Market size is forecast to reach... 
Via iCrowdNewswire
Topics Derivatives
Exposures COVID-19 Derivatives
Gilead's Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients
Via Benzinga
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
From Gilead Sciences, Inc.
Via Business Wire
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.56% on an annualized basis producing an average annual return of 14.71%. Currently, Gilead Sciences has a market... 
Via Benzinga
On Earth Day, Gilead Marks Strides in Environmental Sustainability
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Emissions
Gilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus
Gilead Sciences, Inc. (NASDAQ: GILD) reported firs 
Via Benzinga
Gilead Sciences Announces First Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Gilead Sciences's Earnings Outlook
Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Gilead... 
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
The Daily Biotech Pulse - Tuesday, April,26
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Dividend Stocks Paying Over 5% to Buy Now
Stock markets will return less this year as interest rates rise and cause a recession, so investors should demand higher yield. 
Via InvestorPlace
Gilead Sciences Announces Support for the Robert A. Winn Diversity in Clinical Trials Award Program
SOURCE: Gilead Sciences 
Via 3BL Media
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
From Gilead Sciences, Inc.
Via Business Wire
The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
WHO Backs Pfizer's Oral COVID Antiviral Therapy For High-Risk Patients
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
49 50 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.